Long-term Follow-up of Gene Therapy for Radiation-Induced Xerostomia
← catalyst calendarNCT06544798 · readout ≤ 2,020 d
Sponsored by MeiraGTx, LLC (industry) · MGTX — their whole pipeline →.
Phase
Phase 2
Status
Enrolling by invitation
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
276estimated
Sites
8
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-02 | actual | When the study began enrolling |
| Primary completion | Feb 2032 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2032 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-16 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Intervention
- Genetic: AAV2-hAQP1
Primary outcome
what the primary-completion date above is the date OFNumber of participants with study drug-related adverse events and serious adverse events
measured From study start until Month 60 post-treatment
Permalink · MGTX's whole pipeline · Catalyst calendar · Every registered study · What changed